COVID-19 Vaccine Phase 3 Study Completes Enrollment in Mexico and the USA
Maryland-based Novavax, Inc. announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety, and immunogenicity of the COVID-19 vaccine candidate NVX-CoV2373. About 30,000 participants have been enrolled across 118 sites in the USA and Mexico.
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.
Gregory M. Glenn, President of Research and Development, Novavax, commented in a press release issued on February 22, 2021, “We thank the thousands of volunteers and individuals, including our partners at NIH, the COVID-19 Prevention Network, and trial sites in the USA and Mexico, who enabled rapid recruitment and enrollment in the trial, which we believe is a critical aspect to building vaccine trust and uptake across the globe.”
PREVENT-19 is being conducted with support from U.S. government partners, including the Department of Defense and the Biomedical Advanced Research and Development Authority, which provides up to $1.75 billion in funding under a Department of Defense agreement.
Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.